Geode Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,954,735
| Closed | -$41.9M | – | 4479 |
|
|
2026
Q1 | $41.9M | Buy |
1,954,735
+76,897
| +4% | +$1.08M | ﹤0.01% | 1586 |
|
|
2025
Q4 | $17.5M | Buy |
1,877,838
+116,574
| +7% | +$974K | ﹤0.01% | 2084 |
|
|
2025
Q3 | $12.4M | Buy |
1,761,264
+48,835
| +3% | +$336K | ﹤0.01% | 2287 |
|
|
2025
Q2 | $11.1M | Buy |
1,712,429
+171,964
| +11% | +$1.18M | ﹤0.01% | 2293 |
|
|
2025
Q1 | $12.2M | Buy |
1,540,465
+77,483
| +5% | +$835K | ﹤0.01% | 2166 |
|
|
2024
Q4 | $18.5M | Buy |
1,462,982
+30,285
| +2% | +$421K | ﹤0.01% | 2007 |
|
|
2024
Q3 | $20M | Buy |
1,432,697
+136,458
| +11% | +$1.95M | ﹤0.01% | 1976 |
|
|
2024
Q2 | $17.9M | Sell |
1,296,239
-80,722
| -6% | -$1.18M | ﹤0.01% | 1992 |
|
|
2024
Q1 | $22.8M | Buy |
1,376,961
+28,142
| +2% | +$421K | ﹤0.01% | 1853 |
|
|
2023
Q4 | $19.7M | Buy |
1,348,819
+55,705
| +4% | +$675K | ﹤0.01% | 1932 |
|
|
2023
Q3 | $15.9M | Buy |
1,293,114
+367,898
| +40% | +$4.8M | ﹤0.01% | 1967 |
|
|
2023
Q2 | $11M | Buy |
925,216
+336,740
| +57% | +$4.4M | ﹤0.01% | 2231 |
|
|
2023
Q1 | $7.87M | Buy |
588,476
+7,992
| +1% | +$156K | ﹤0.01% | 2399 |
|
|
2022
Q4 | $12.5M | Buy |
580,484
+25,854
| +5% | +$530K | ﹤0.01% | 2102 |
|
|
2022
Q3 | $11.1M | Buy |
554,630
+112,271
| +25% | +$2.39M | ﹤0.01% | 2169 |
|
|
2022
Q2 | $7.92M | Buy |
442,359
+119,664
| +37% | +$1.24M | ﹤0.01% | 2421 |
|
|
2022
Q1 | $3.2M | Buy |
322,695
+113,352
| +54% | +$1.5M | ﹤0.01% | 3026 |
|
|
2021
Q4 | $3.53M | Buy |
209,343
+22,716
| +12% | +$467K | ﹤0.01% | 3081 |
|
|
2021
Q3 | $4.43M | Buy |
186,627
+151,692
| +434% | +$3.64M | ﹤0.01% | 2974 |
|
|
2021
Q2 | $795K | Buy |
+34,935
| New | +$729K | ﹤0.01% | 3719 |
|
Other funds holding DAWN
Geode Capital Management's DAWN Position: Q2 2026 in Review
Geode Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 1,954,735 shares — an estimated $41.9M sold.
Geode Capital Management first reported a position in DAWN in Q2 2021 and held it in 20 quarters. The position peaked at $41.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Geode Capital Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Geode Capital Management sold 1,954,735 Day One Biopharmaceuticals shares in Q2 2026, an estimated $41.9M.
- Geode Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 20 quarters.
- Geode Capital Management's Day One Biopharmaceuticals position peaked at $41.9M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.